Novartis’ blockbuster heart med Entresto snags FDA approval in larger patient group

Novartis’ blockbuster heart med Entresto snags FDA approval in larger patient group

Source: 
Fierce Pharma
snippet: 

Novartis' heart failure drug Entresto has been on the ascent after a slower-than-expected debut on the market, and now the drug has an expanded FDA label that could widen its reach to millions of new patients.